Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto

Research output: Contribution to journalArticle

30 Citations (Scopus)


Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P

Original languageEnglish
Pages (from-to)210-220
Number of pages11
JournalInternational Journal of Clinical Oncology
Issue number3
Publication statusPublished - Jun 2011



  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this